Stock Ratings / Health Care / TSHA / financials

LYCA (59) VOR (37) IMCR (31) REPL (46) ⌘ Pro Terminal →

Taysha Gene Therapies Inc. (TSHA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$4.22 -0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.21

Taysha Gene Therapies Inc. (TSHA) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $1.38B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.21 (-0.23%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TSHA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY TSHA SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (28% of score)

FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 43.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (26% of score)

Altman Z-Score 5.67 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$4.49-19.4% Next Q

Q2 (-2Q)

Grade D$3.62+9.4% Next Q

Q3 (-1Q)

Grade D$3.96+6.6% Next Q

Current

Grade D-$4.22-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TSHA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TSHA currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.82) and Max Pain ($4.43) forces dealer call-delta covering toward $7.67.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TSHA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TSHA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How TSHA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $15.5M

FY24

Rev $8.3M

FY25

Rev $9.8M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$9.8M	52%	-80%	-$109.0M	-$93.8M	-45%
FY 2024	$8.3M	52%	-80%	-$89.3M	-$81.6M	-45%
FY 2023	$15.5M	52%	-80%	-$111.6M	-$73.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TSHA)

✓Walkthrough of TSHA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TSHA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.96%▼ DESCENDING CHANNEL

2026-10-30O $4.18H $4.25L $4.07C $4.22VOL 1.50M

RES: $6.02SUP: $3.05SMA50: $4.82SMA200: $5.32

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TSHA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TSHA Butterfly Map → + Track TSHA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TSHA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TSHA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TSHA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TSHA)

Health Care Rank #542 of 1016 ⚔️ LYCA vs TSHA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TSHA vs. LYCA, VOR, IMCR, REPL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Taysha Gene Therapies Inc. (TSHA) ranks #542 by composite RQD confidence (43/100, grade D-) and #316 by equity capitalization ($1.38B). Within this direct 5-issuer industry benchmark cohort, TSHA leads on earnings valuation at N/A trailing P/E, while TSHA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LYCA currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with TSHA at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TSHA ACTIVE Taysha Gene Therapies Inc.	D-	43/100	—	—	-35.0%	-0.24%	$1.38B	Benchmark Subject
LYCA Lycia Therapeutics Inc.	C-	59/100	—	—	—	+10.70%	$1.44B	/lyca-vs-tsha →
VOR Vor Biopharma Inc.	D-	37/100	—	—	-35.0%	+1.26%	$1.24B	/vor-vs-tsha →
IMCR Immunocore Holdings plc	E	31/100	—	96.0%	-35.0%	-4.11%	$1.61B	/imcr-vs-tsha →
REPL Replimune Group Inc.	D	46/100	—	—	-35.0%	+8.28%	$1.65B	/repl-vs-tsha →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001806310

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Taysha Gene Therapies Inc. (TSHA) reported GAAP revenue of $9.8M (+17.3% vs. FY2024 revenue of $8.3M , and -36.7% cumulative change since FY2023) , GAAP net income of -$109.0M, operating cash flow of -$93.1M, and free cash flow of -$93.8M (-15.0% YoY). On the balance sheet, TSHA closed FY2025 with $343.3M in total assets against $50.1M in total debt (Altman Z-Score: 5.67, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$9.8M	-$109.0M	-$93.1M	-$93.8M	$343.3M	$50.1M
FY2024 (FY)	2024-12-31	$8.3M	-$89.3M	-$81.2M	-$81.6M	$160.4M	$43.9M
FY2023 (FY)	2023-12-31	$15.5M	-$111.6M	-$73.0M	-$73.0M	—	—

3. TSHA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TSHA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Taysha Gene Therapies Inc. (NASDAQ: TSHA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $4.22 (-0.24% 1D, market cap $1.38B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TSHA ranks #542 in composite RQD confidence.

How does TSHA compare to LYCA and VOR in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TSHA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYCA (Lycia Therapeutics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $1.44B) and VOR (Vor Biopharma Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.24B). Among the 5-stock peer group, TSHA leads on earnings multiple (N/A) while TSHA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TSHA?

Per TSHA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001806310), Taysha Gene Therapies Inc. generated $9.8M in revenue (+17.3% YoY), -$109.0M in net income, and -$93.8M in free cash flow against $343.3M in total assets and $50.1M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TSHA trading relative to its 50-day, 200-day, and 52-week technical levels?

TSHA last traded at $4.22 (-0.24% on volume of 2,057,824 shares), positioning the stock -12.45% below its 50-day simple moving average ($4.82) and -20.68% below its 200-day simple moving average ($5.32). Across its 52-week range of $3.46 to $7.30, TSHA sits at the 19.8% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.69 to $4.75).

TSHA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Taysha Gene Therapies Inc. (TSHA)?

In FY 2025 (10-K), TSHA converted $9.8M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: TSHA RQD Cockpit TSHA 12M Forecast TSHA Earnings & Move TSHA Dividends & DRIP TSHA Insiders & 13F TSHA Whale Options TSHA Profit Sankey TSHA News & Why